Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial

BACKGROUND: Interstitial lung disease (ILD) frequently complicates systemic autoimmune disorders resulting in considerable morbidity and mortality. The connective tissue diseases (CTDs) most frequently resulting in ILD include: systemic sclerosis, idiopathic inflammatory myositis (including dermatom...

Descripción completa

Detalles Bibliográficos
Autores principales: Saunders, Peter, Tsipouri, Vicky, Keir, Gregory J., Ashby, Deborah, Flather, Marcus D., Parfrey, Helen, Babalis, Daphne, Renzoni, Elisabetta A., Denton, Christopher P., Wells, Athol U., Maher, Toby M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471887/
https://www.ncbi.nlm.nih.gov/pubmed/28619061
http://dx.doi.org/10.1186/s13063-017-2016-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471887/
https://www.ncbi.nlm.nih.gov/pubmed/28619061
http://dx.doi.org/10.1186/s13063-017-2016-2

Ejemplares similares